MedTrace Logo

Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)

NCT01495741 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2022-02-04

No results posted yet for this study

Summary

This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®). The occurrence of identified and potential clinically important risks will also be assessed.

Conditions

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-01
Primary Completion
2017-12-18
Completion
2017-12-18

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01495741 on ClinicalTrials.gov